4-Antibody AG, a privately held Swiss company that develops antibodies for auto-immune and inflammatory diseases and oncology, has appointed Richard Mason as CEO.
Dr Mason previously worked for Advent Venture Partners, an investor in 4-Antibody. Before that, he was head of the business development team at Cambridge Antibody Technology Plc before it was acquired by AstraZeneca.
Copyright 2008 Evernow Publishing Ltd